Navigation Links
Pulmo BioTech Announces an Increase in its Stake in PulmoScience
Date:5/9/2008

ng technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible t
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
2. Pulmo BioTech Announces Appointment of Chief Financial Officer
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
5. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology
8. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
9. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
10. DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members
11. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2014)... Synedgen announced today the award ... Phase I contract from the National Cancer Institute ... to demonstrate proof-of-concept activity of Synedgen’s proprietary treatment ... tissue damage to the lining of the gastrointestinal ... award, Synedgen will complete efficacy studies for its ...
(Date:9/26/2014)... China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... 2014 annual general meeting of shareholders at its Hong ... Garden Road, Central, Hong Kong , at 9:00 ... Eastern Time on December 11, 2014). Shareholders of record ...
(Date:9/26/2014)... Molecular Biology deals with the ... regulation of cellular activity and its behaviour. It emphasise ... with its environment within the genome. Knowledge on molecular ... therapeutic methodologies for the diagnosis, prognosis and the treatment ... Dr. Srinubabu Gedela, MD of OMICS Publishing Group ...
(Date:9/26/2014)... “Inflamax’s Clinical Data Management group is a SCDM ... allows us to support our group in maintaining the ... Director of Data Management at Inflamax. “Being an ... Clinical Data Managers have been certified by passing the ... offering only the best services to our clients, by ...
Breaking Biology Technology:Synedgen Awarded National Cancer Institute Funding for Promising New Treatment for Medical Radiation-induced Bowel Injury 2China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 11, 2014 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 3
... N.Y., Nov. 5 BioSpecifics Technologies Corp. (Nasdaq: ... today announced its financial results for the third quarter ... happy that, in September of this year, the FDA,s ... 12-0, the approval of XIAFLEX(TM) for the treatment of ...
... November 5, 2009 Senomyx, Inc. (Nasdaq: SNMX ), ... discover novel flavor ingredients for the food, beverage, and ingredient ... results for the third quarter ended September 30, 2009. ... compared to $4.0 million for the third quarter of 2008, ...
... PLYMOUTH MEETING, Pa., Nov. 5 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... the Company plans to release third quarter 2009 financial results ... The Company will hold a conference call ... quarter 2009 results. Listeners may access the call by,dialing ...
Cached Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BMP Sunstone to Report Third Quarter 2009 Financial Results 2
(Date:9/29/2014)... Juan Manuel Santos has presented Dr. Cristin Samper, ... with the prestigious Order of San Carlos. , ... foreign civilians and military officers who have made ... field of international relations. , An international authority ... was invited to the Colombian Residence in New ...
(Date:9/29/2014)... Va.September 29, 2014Research!America,s 19th annual Advocacy Awards ... who are trailblazers in advancing medical progress to ... nation. The event will take place on Wednesday, ... Auditorium in Washington, DC. , The 2015 Advocacy ... Robin Roberts; Michael Milken, founder of the Milken ...
(Date:9/29/2014)... 29, 2014 Growing Demand ... with Increasing Security Concerns Continue to Propel Biometrics ... is one of the fastest growing ... biometrics systems, majorly in various government projects such ... modality based biometrics dominates the country,s biometrics market, ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... Bar Harbor, Maine - Currently, 5-8% of the ... ( www.niaid.nih.gov ). Many of these are chronic ... aggregate within a single family, suggesting they are ... To help researchers investigate these common pathways, ...
... UT Southwestern Medical Center have eliminated non-small cell lung ... called BEZ235 in combination with low-dose radiation. In ... Cancer Research , UT Southwestern researchers found that if ... tumor cells with otherwise nontoxic radiation, the drug blocked ...
... are reporting results of one of the first studies ... anti-odor, anti-bacterial socks now on the market. Their findings, ... Environmental Science & Technology , may suggest ways ... these particles to the environment, where they could harm ...
Cached Biology News:UT Southwestern researchers use drug-radiation combo to eradicate lung cancer 2
... DNA120OP is specifically engineered for efficient drying ... incorporates a glass cover and a post-trap ... unattended, odor-free processing of samples in ammonium ... Synthetic Oligos , ...
... Maxi MB (for aqueous, other low volatility ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... The DNA120 is a dedicated concentrator for ... precipitates of DNA/RNA. The integrated system combines ... pump. The compact design, automatic pump and ... run time; one for heater time), makes ...
... 1 Block MBS Start up kit. Includes ... and choice of 1 MultiBlock satellite ... 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding uniformity. ...
Biology Products: